U.S. Markets closed
  • S&P Futures

    4,383.25
    +3.50 (+0.08%)
     
  • Dow Futures

    34,781.00
    +60.00 (+0.17%)
     
  • Nasdaq Futures

    14,947.25
    -5.50 (-0.04%)
     
  • Russell 2000 Futures

    2,212.80
    +1.90 (+0.09%)
     
  • Crude Oil

    71.40
    +0.14 (+0.20%)
     
  • Gold

    1,814.30
    -7.90 (-0.43%)
     
  • Silver

    25.39
    -0.19 (-0.74%)
     
  • EUR/USD

    1.1878
    +0.0001 (+0.0119%)
     
  • 10-Yr Bond

    1.1740
    -0.0650 (-5.25%)
     
  • Vix

    19.46
    +1.22 (+6.69%)
     
  • GBP/USD

    1.3893
    +0.0010 (+0.0722%)
     
  • USD/JPY

    109.2100
    -0.0990 (-0.0906%)
     
  • BTC-USD

    39,020.20
    -721.94 (-1.82%)
     
  • CMC Crypto 200

    951.76
    -9.14 (-0.95%)
     
  • FTSE 100

    7,081.72
    +49.42 (+0.70%)
     
  • Nikkei 225

    27,543.69
    -237.33 (-0.85%)
     

GCANRx Announces Collaboration with Renowned Cannabis Research Lab

·5 min read

BALTIMORE, March 16, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company (OTCQB: GCAN), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoid products is proud to announce a collaboration with Israel-based cannabis lab, Phytor LTD, a leader in the research and development of plant-based therapeutics.

Under this collaboration, the companies will develop and commercialize novel therapeutics for dermatological, chronic ailments and other conditions that have been notoriously difficult to treat using conventional therapies. The focus will be on cannabinoid and botanical-based wellness solutions, products and therapies that have consumer or commercial use cases.

Phytor is led by Dr. Yehoshua Maor, a pharmacologist, toxicologist and cannabis expert who completed his graduate studies at the Hebrew University under the supervision of renowned professor, Dr. Raphael Mechoulam, one of the most acclaimed cannabis researchers, and known throughout the world as the “Father of Cannabis Research''. Dr. Maor’s research focused on both chemistry and biology of cannabinoids, which led him to gain immense knowledge in the bioactivity, pharmacokinetics and synthesis of cannabinoids, and an advanced understanding of their relevant therapeutic potential. As a graduate student he received awards for outstanding scientific presentations at the International Cannabis Research Society (ICRS). He was also a postdoctoral fellow of experimental medicine at the Harvard Institutes of Medicine before accepting a lead position at the Hebrew University Center of Excellence in Agriculture and Environmental Health. Under his direction, Phytor has become a world renowned cannabis R&D facility with an established team of multidisciplinary PhDs skilled in advanced science and research of pharmacological, agricultural and genetic characteristics of cannabinoids.

“We are delighted to be joining forces with GCANRx to collaborate on cutting edge cannabinoid and botanical-based therapies. Many of today’s conventional treatments require hormone based actives that cannot be used long term and have a host of side effects. Our focus is on developing natural, botanical compounds that are similar in their properties to existing pharmaceutical standards of care, but which can provide natural, rapid and sustained relief to patients who have long sought safer and more effective treatments”, stated Dr. Maor.

GCANRx CEO, Aitan Zacharin, had this to say, “We are excited to be forming this collaborative partnership with Phytor, and harnessing their tremendous knowledge, resources and industry expertise. Dr. Maor and his team have a stellar record of staying ahead of the emerging science on plant-based therapeutics, particularly those involving cannabinoids, and have demonstrated their expertise in isolating active compounds of plant origin and developing them into highly valuable therapeutic agents that improve patient and consumers’ lives.” Mr. Zacharin concluded, “As we begin to explore combining our delivery platform with Phytor’s development capabilities we will be looking for low hanging opportunities that we can tackle to broaden the applicability of our technology.”

- ENDS -

Signup To Receive The Latest News About GCANRx.

About The Greater Cannabis Company

The Greater Cannabis Company (OTCQB: GCAN) is a fully reporting publicly traded biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems. Greater Cannabis deploys its technology platform for use in the cannabis industry. The Company’s conveyance platform can be utilized to deliver cannabinoids without the harmful side effects found with other routes of cannabinoid administration. The technology is versatile in that patients can now receive lower dosing, enhanced bioavailability, and controlled rapid and delayed release using non-irritant oral eluting and transdermal patches. Greater Cannabis’ mission is to bring our technology to the global market through partnerships with leading cannabis and pharmaceutical companies, for the benefit of patients and consumers. More information on the Greater Cannabis Company and its technology can be found on the Company’s website, www.gcanrx.com.

Greater Cannabis Co. Disclaimer: Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include the uncertainty regarding viability and market acceptance of the Company's products and services, the ability to complete development plans in a timely manner, changes in relationships with third parties, product mix sold by the Company and other factors described in the Company's most recent periodic filings with the Securities and Exchange Commission, including its 2019 Annual Report on Form 10-K and quarterly reports on Form 10-Q.

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact: The Greater Cannabis Company, Inc.
443-738-4051
info@gcanrx.com
www.gcanrx.com